# reload+after+2024-01-20 19:46:06.777031
address1§10770 Wateridge Circle
address2§Suite 200
city§San Diego
state§CA
zip§92121
country§United States
phone§858 546 0004
website§https://www.maravai.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
fullTimeEmployees§670
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Carl W. Hull', 'age': 64, 'title': 'Co-Founder & Executive Chairman', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 1453673, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William E. Martin III', 'age': 48, 'title': 'Chief Executive Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 2069616, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin M. Herde', 'age': 51, 'title': 'Executive VP & CFO', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 778276, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Peter Michael Leddy Ph.D.', 'age': 60, 'title': 'Executive VP & Chief Administrative Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 756996, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Christine  Dolan', 'age': 55, 'title': 'Executive Vice President of Biologics Safety Testing', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 755967, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Debra  Hart', 'title': 'Senior Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kurt  Oreshack', 'age': 42, 'title': 'Executive VP, General Counsel & Secretary', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 701398, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Becky  Buzzeo', 'title': 'Executive VP & Chief Commercial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kate E. Broderick Ph.D.', 'title': 'Chief Innovation Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher  Benoit', 'title': 'Executive Vice President of Enzymes', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§10
compensationRisk§4
shareHolderRightsRisk§7
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.185
priceToSalesTrailing12Months§3.9173403
currency§USD
dateShortInterest§1702598400
forwardEps§0.05
exchange§NMS
quoteType§EQUITY
shortName§Maravai LifeSciences Holdings, 
longName§Maravai LifeSciences Holdings, Inc.
firstTradeDateEpochUtc§1605882600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§90f7b200-f7ec-34b8-a9f6-f1c65d6979bf
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§6.0
targetMeanPrice§8.91
targetMedianPrice§8.57
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§10
quickRatio§8.036
grossMargins§0.60933995
ebitdaMargins§0.29193002
trailingPegRatio§None
